Major Players - Crispr And Cas Gene Industry

 

Over the course of the forecast period, the COVID-19 pandemic is anticipated to propel the growth of the worldwide CRISPR and CAS gene market. The demand for effective diagnostic tools has grown along with the number of COVID-19 cases, which pushed the CRISPR and CAS gene market participants to create diagnostic tools for COVID-19 detection. Additionally, in order to battle the COVID-19 pandemic, the regulatory authorities provided emergency use authorizations to the goods created by market participants. The increased product approvals assisted market participants in diversifying their product portfolios, which allowed the market participants to enhance their market share in the CRISPR and CAS gene market.

The market for CRISPR and CAS genes is anticipated to reach US$ 830.7 Mn in 2020 and is projected to grow at a CAGR of 22.8% from 2020 to 2027.

 Key Competitors in the Crispr And Cas Gene Industry:

1. Thermo Fisher Scientific Inc.:

Thermo Fisher Scientific sells reagents for life sciences, laboratory supplies, and equipment for diagnostics. Founded 1956. United States headquarters.

2. Merck KGaA (Sigma-Aldrich):

The three primary business sectors of Merck KGaA are life sciences, performance materials, and healthcare. Researchers in academia and applied disciplines, such as the biopharmaceutical business, are supplied with laboratory supplies and equipment by the life sciences section. Established in 1891. German headquarters in Darmstadt. A legally binding deal has been struck by Merck to buy the chemical division of Mecaro Co. Ltd. (Mecaro), a publicly traded Korean manufacturer of heater blocks and chemical precursors for semiconductors.

3. OriGene Technologies, Inc.:

a supplier of genome-centric research instruments for the pharmaceutical and biotech industries, with the goal of creating genome-wide knockout cells from widely used lab cell lines. created in 1996. United States headquarters. CFIUS Notifies BRIEF-Zhongyuan Union Cell of Its Intent to Indirectly Acquire Origene Technologies Inc. 

4. Cellecta, Inc.:

a provider of genomics goods and services for the advancement of peptide screening and high-throughput RNAi technology. created in 2006. United States headquarters. Partnering with CELLECTA, Inc. to Launch Tissue 2 TargetTM Services is THE CURELINE GROUP.

5. Agilent Technologies, Inc.:

Agilent, which was first separated from Hewlett-Packard in 1999, has grown into a major player in the life sciences and diagnostics industries. With its three operating segments—life science and applied tools, cross lab (containing of consumables and services connected to life science and applied tools), and diagnostics and genomics—Agilent's measuring solutions currently serve a wide range of clients. The most recent acquisitions include Resolution Bioscience (Mar 2021), PSS Polymer Standards Service (Aug 2022), and Avida Biomed (Jan 2023).

6. Applied StemCell, Inc.:

Creator of gene modification methods that make use of skills in stem cells and genome editing to promote industrial biotechnology and next-generation biomedical research. Abcam plc, a leader in the development of life science reagents and technologies, was pleased to announce in 2020 that it had acquired the gene editing platform and oncology product line of Applied StemCell, Inc. (ASC) for use in life science research and diagnostic applications. ASC was founded in 2008 and has its headquarters in U.S.

7. Mirus Bio LLC:

a company that offers gene transfer technology for the benefit of the pharmaceutical sector. The business focuses on the discovery and development of cutting-edge nucleic acid-based technologies, such as a unique RNAi (ribonucleic acid interference) delivery platform, to give life scientists cutting-edge equipment for gene expression, the production of biotherapeutic proteins, the creation of viruses, and genome editing. Established in 1995. United States headquarters.

Definition:

CRISPR/Cas9 edits genes by precisely cutting DNA and then letting natural DNA repair processes to take over.